A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.

NCT01743989 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

620

Enrollment

INDUSTRY

Sponsor class

Conditions

Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Interventions

DRUG: Nilotinib

Sponsor

Novartis Pharmaceuticals